## Össur hf.

Condensed Consolidated Financial Statements

September 30th 2010

Össur hf. Grjothalsi 5 110 Reykjavik Id-no. 560271-0189

## Össur hf.

# Condensed Consolidated Financial Statements

## September 30th 2010

## **Table of Contents**

Statement by the Board of Directors and President and CEO	2
Financial Ratios	3
Consolidated Income Statements	4
Consolidated Statements of Comprehensive Income	5
Consolidated Balance sheets	6
Consolidated Statements of Cash Flows	8
Consolidated Statements of Changes in Equity	9
Notes to the Condensed Consolidated Financial Statements	10

## Statement by the Board of Directors and President and CEO

The Condensed Interim Consolidated Financial Statements of Össur hf. for the period from 1 January to 30 September 2010 consist of the Financial Statements of Össur hf. and its subsidiaries. The Financial Statements are prepared in accordance with International Financial Reporting Standards for Interim Financial Reporting, IAS 34 as adopted by the EU. The Condensed Interim Consolidated Financial Statements are not audited nor reviewed by the Company's auditors.

The total sales of the Ossur Consolidation amounted to USD 263.9 million. The net profit amounted to USD 27.3 million and according to the Balance Sheets the total assets of the Ossur Consolidation amounted to USD 605.4 million at the end of period, liabilities were 270.8 million, and equity was 334.6 million.

It is our opinion that these Condensed Interim Consolidated Financial Statements present all the information necessary to give a true and fair view of the Company's assets and liabilities, financial position at 30 September 2010 and operating performance of the period ended 30 September 2010.

The Board of Directors and the President and CEO of Össur hf. have today discussed the Condensed Interim n them by

Consolidated Financial Statements for the period means of their signatures.	l from 1 January to 30 September 2010 and confirm
Reykjavik, 25 October 2010	
Board of Directors	
Niels Jacobsen Chairman of the Board	
Arne Boye Nielsen	Kristjan T. Ragnarsson
Thordur Magnusson	Svafa Gronfeldt
President and CEO	
Jon Sigurdsson	

## **Financial Ratios**

Consolidated statement						
		YTD 2010	YTD 2009	2009	2008	2007
Income Statement						
Net sales	USD '000	263,926	242,709	330,580	346,835	331,966
Gross profit	USD '000	164,088	148,807	201,815	214,203	192,033
Operating expenses <sup>2</sup>	USD '000	119,815	114,654	154,071	167,678	171,160
Profit from operations	USD '000	45,885	34,518	48,240	55,958	39,716
Net profit	USD '000	27,301	14,688	22,762	28,488	7,580
EBITDA	USD '000	56,482	49,176	66,988	79,440	64,392
Balance sheet						
Total assets	USD '000	605,384	616,826	628,217	603,778	635,821
Equity	USD '000	334,554	276,470	312,223	249,648	250,282
Net interest-bearing debt (NIBD)	USD '000	128,493	197,230	157,633	234,281	283,106
Cash flow						
Cash generated by operations	USD '000	47,697	56,465	85,770	71,460	61,528
Cash provided by operating activities	USD '000	30,842	46,320	69,155	52,835	45,701
Cash flows from investing activities	USD '000	(7,019)	(5,330)	(16,423)	(6,648)	(17,781)
Cash flows from financing activities	USD '000	(37,331)	(23,618)	(4,284)	(30,610)	(25,289)
Free Cash flow	USD '000	27,634	41,079	60,238	46,040	38,841
Key figures						
Sales Growth USD	%	8.7	(9.2)	(4.7)	4.5	33.5
Operating margin	0/0	17.4	14.2	14.6	16.0	12.0
EBITDA margin	0/0	21.4	20.3	20.3	22.9	19.4
Equity ratio	0/0	55.3	44.8	49.7	41.3	39.4
Ratio of net debt to EBITDA 1		1.7	3.0	2.4	2.9	4.4
Ratio of debt to EBITDA 1		2.6	3.8	3.5	3.3	4.6
Current ratio		2.3	1.9	2.3	1.1	0.9
Return on equity <sup>1</sup>	%	11.4	7.2	8.1	11.0	4.0
Market						
Market value of equity <sup>3</sup>	USD '000	857,212	419,303	529,151	349,263	672,024
Number of shares	Millions	454	423	454	423	423
Price/earnings ratio, (P/E) 1		24.6	22.2	23.2	12.3	88.7
Diluted EPS <sup>1</sup>	US Cent	7.84	4.46	5.30	6.73	1.94
Diluted Cash EPS <sup>1</sup>	US Cent	11.10	9.22	9.66	12.29	8.24

## Notes

- 1. Financial ratios for YTD 2010 and YTD 2009 are based on operations for the preceding 12 months.
- 2. Excluding other income.
- 3. Market value based on closing price at 30.09.2010 on Nasdaq OMX, Iceland and Denmark.

# Consolidated Income Statements for the period 1.1.- 30.9.2010 and 1.1.- 30.9.2009

	Notes	2010 YTD	2009 YTD	2010 Q3	2009 Q3
Net sales	4	263,926	242,709	87,437	84,184
Cost of goods sold	·	(99,838)	(93,902)	(32,991)	(32,463)
Gross profit		164,088	148,807	54,446	51,721
Other income		1,612	365	130	18
Sales and marketing expenses		(71,388)	(69,116)	(22,980)	(21,948)
Research and development expenses		(14,583)	(13,948)	(4,743)	(4,170)
General and administrative expenses	<u> </u>	(33,844)	(31,590)	(11,122)	(10,725)
Profit from operations		45,885	34,518	15,731	14,896
Financial income		280	185	130	45
Financial expenses		(11,733)	(11,514)	(4,020)	(4,047)
Net exchange rate difference		1,941	(3,463)	(6,514)	(4,196)
Net financial income / (expenses)	7	(9,512)	(14,792)	(10,404)	(8,198)
Profit before tax		36,373	19,726	5,327	6,698
Income tax	8 _	(9,072)	(5,038)	(1,312)	(1,938)
Net profit		27,301	14,688	4,015	4,760
Attributable to:					
Owners of the Company		26,895	14,688	3,896	4,760
Non-controlling interests		406	0	119	0
O	_	27,301	14,688	4,015	4,760
Earnings per Share					
Basic Earnings per Share		6.06	3.47	0.88	1.13
Diluted Earnings per Share	_	6.05	3.47	0.88	1.13

# Consolidated Statements of Comprehensive Income for the period 1.1.- 30.9.2010 and 1.1.- 30.9.2009

	Notes	2010 YTD	2009 YTD	2010 Q3	2009 Q3
Net profit		27,301	14,688	4,015	4,760
Other comprehensive income  Gain / (loss) on hedge of a net investment in foreign operations		2,644 2,388 (9,111) (806)	(2,118) (422) 14,061	(4,067) 468 22,209 462	(2,353) (385) 10,257
Other comprehensive income (net of tax)	. <u> </u>	(4,885)	11,852	19,072	7,589
Total comprehensive income	_	22,416	26,540	23,087	12,349
Attributable to Owners of the Company Non-controlling interests		22,010 406	26,540 0	22,968 119	12,349 0
0		22,416	26,540	23,087	12,349

## **Consolidated Balance Sheets**

Assets	•
--------	---

	Notes	30.09.2010	31.12.2009
Non-current assets			
Property, plant and equipment	10	29,939	32,286
Goodwill	11	331,494	334,844
Other intangible assets	12	30,524	35,382
Other financial assets	14	5,152	3,567
Deferred tax asset	22	37,732	42,367
		434,841	448,446
Current assets			
Inventories	16	44,185	43,526
Accounts receivables	17	49,310	43,693
Other assets	17	10,077	10,413
Assets classified as held for sale	10	1,190	2,308
Bank balances and cash	15	65,781	79,831
	_	170,543	179,771

Total assets 605,384 628,217

## 30 September 2010 and 2009

## **Equity and liabilities**

	Notes	30.09.2010	31.12.2009
Equity			
Issued capital	18	201,997	201,997
Reserves		1,006	5,582
Retained earnings		130,542	103,647
Equity attributable to owners of the Company	-	333,545	311,226
Non-controlling interest in equity	_	1,009	997
Total equity	-	334,554	312,223
Non-current liabilities			
Borrowings	20	173,517	210,282
Deferred tax liabilities	22	10,352	11,024
Provisions	23	5,465	5,744
Other financial liabilities	21	7,606	9,995
	-	196,940	237,045
Current liabilities			
Borrowings	20	20,757	27,182
Accounts payable		15,625	13,353
Taxes payable		4,078	2,452
Provisions	23	2,434	2,686
Other liabilities	25	30,996	33,276
	-	73,890	78,949
Total equity and liabilities	=	605,384	628,217

# Consolidated Statements of Cash Flows for the period 1.1.- 30.9.2010 and 1.1.- 30.9.2009

	Notes	YTD 2010	YTD 2009
Cash flows from operating activities			
Profit from operations		45,885	34,518
Depreciation and amortization	10, 12	10,597	14,659
Gain / loss on disposal of assets		(1,051)	530
Change in provisions		(389)	(1,171)
Changes in operating assets and liabilities	_	(7,345)	7,929
Cash generated by operations		47,697	56,465
Interest received		110	189
Interest paid		(15,125)	(7,303)
Taxes paid	· <u> </u>	(1,840)	(3,031)
Net cash provided by operating activities	_	30,842	46,320
Cash flows from investing activities			
Purchase of fixed assets	10, 12	(5,854)	(5,947)
Proceeds from sale of fixed assets	,	2,646	706
Acquisition of subsidiaries	13	(2,219)	0
Changes in financial assets		(1,592)	(89)
	_	(7,019)	(5,330)
Cash flows from financing activities			
Proceeds from long-term borrowings		(132)	2,328
Repayments of long-term borrowings		(36,805)	(25,946)
Dividends from subsidiaries paid to non-controlling interests		(394)	0
	_	(37,331)	(23,618)
Net change in cash		(13,508)	17,372
Effects of foreign exchange rate adjustments		(542)	760
Cash at beginning of period	_	79,831	30,906
Cash at end of period	_	65,781	49,038
Additional information regarding cash flow	9		

## Consolidated Statements of Changes in Equity for the period ended 30 September 2010

<u>-</u>	Share capital	Share premium	Statutory reserve	Stock option reserve	Hedging reserve	Translation reserve	Accumulated profits	Attributable to owners of the parent	Non- controlling interests	Total equity
Balance at 1 January 2009	4,821	168,081	1,205	989	(8,053)	1,602	81,003	249,648		249,648
Net profitLoss on hedge of a net investment in							14,688	14,688		14,688
foreign operations net of tax  Loss on cash flow hedges net of tax  Translation difference of shares in foreign operations					(367)	(1,842) 14,061		(1,842) (367) 14,061		(1,842) (367) 14,061
Total comprehensive income for the period	0	0	0	0	(367)	12,219	14,688	26,540	0	26,540
Share option charge for the period				282				282		282
Balance at 30 September 2009	4,821	168,081	1,205	1,271	(8,420)	13,821	95,691	276,469	0	276,469
Balance at 1 January 2010	5,068	196,929	1,267	1,415	(8,480)	11,380	103,647	311,226	997	312,223
Net profit							26,895	26,895	406	27,301
Gain on hedge of a net investment in foreign operations net of tax					1,959	2,744 (9,588)		2,744 1,959 (9,588)		2,744 1,959 (9,588)
Total comprehensive income for the period	0	0	0	0	1,959	(6,844)	26,895	22,010	406	22,416
Payment of dividends				309				0 309	(394)	(394) 309
Balance at 30 September 2010	5,068	196,929	1,267	1,724	(6,521)	4,536	130,542	333,545	1,009	334,554

#### 1. General information

Össur hf. (the Company) is a global orthopaedics company, specializing in the development, manufacturing and sales of prosthetics, bracing and supports and compression therapy products. The principal market areas of the Company are Americas, Europe, Middle East and Africa (EMEA) and Asia, which are served by subsidiaries in the United States, Canada, Sweden, Norway, the Netherlands, UK, France, Australia, Spain, Swiss, S-Africa and China in addition to the Iceland-based parent company.

The main production of the Company is conducted at Össur hf. in Iceland, Gibaud Group (La Tour Finance) in St. Etienne, Trevoux in France and at Össur Americas in California USA. Part of the production is outsourced to Asia.

According to the Company's organizational structure, the consolidation is divided into four main functions; Corporate Finance, responsible for overall financial management; Manufacturing & Operations, responsible for quality control and all production, inventory management and distribution; Research & Development, responsible for product development and product management; Sales & Marketing responsible for sales and marketing through the subsidiaries.

#### 2. Summary of Significant Accounting Policies

#### 2.1 Statement of compliance

The Condensed Interim Consolidated Financial Statements have been prepared in accordance with IAS 34, Interim Financial Reporting, as adopted by the EU. They do not include all of the information required for full annual Financial Statements, and should be read in conjunction with the Company's Annual Financial Statements for the period ended 31 December 2009.

#### 2.2 Basis of preparation

The Condensed Interim Consolidated Financial Statements have been prepared under the historical cost basis except for the revaluation of financial instruments. The accounting policies adopted are consistent with those followed in the preparation of the Company's Annual Financial Statements for the period ended 31 December 2009.

#### 3. Quarterly statements

	Q3 2010	Q2 2010	Q1 2010	Q4 2009	Q3 2009
_	2010	2010	2010	2007	2007
Net sales	87,437	90,021	86,468	87,871	84,184
Cost of goods sold	(32,991)	(34,467)	(32,380)	(34,863)	(32,463)
Gross profit	54,446	55,554	54,088	53,008	51,721
Other income	130	64	1,418	131	18
Sales and marketing expenses	(22,980)	(23,645)	(24,763)	(23,451)	(21,948)
Research and development expenses	(4,743)	(4,738)	(5,102)	(5,132)	(4,170)
General and administrative expenses	(11,122)	(11,224)	(11,498)	(10,834)	(10,725)
Profit from operations	15,731	16,011	14,143	13,722	14,896
Net financial income /expenses	(3,890)	(3,802)	(3,761)	(4,004)	(4,002)
Net exchange rate difference	(6,514)	5,692	2,763	793	(4,196)
Total financial income/(expenses)	(10,404)	1,890	(998)	(3,211)	(8,198)
Profit before tax	5,327	17,901	13,145	10,511	6,698
Income tax	(1,312)	(4,308)	(3,452)	(2,437)	(1,938)
Net profit	4,015	13,593	9,693	8,074	4,760
EBITDA	19,082	19,568	17,832	17,812	19,355

In quarter two and three of last year the Company received incorrect information relating to the accrued position on its interest rate swap agreements. This was corrected before year-end 2009. However, the financial expenses in the Financial statement of 30.6.2009 and 30.9.2009 were understated. The effect on interest expense in Q2 2009 is 1.145 and in Q3 2009, 1.245. The quarterly split has been adjusted in the comparative figure in this Financial Statement. The adjustment has no effect on the total 2009 result.

## 4. Net sales

Specified according to geographical segments:

Americas       136,303       118,969         EMEA       115,661       113,209         Asia       11,962       10,532         263,926       242,709         Specified according to product lines:         Prosthetics         In Jayse       109,537         Bracing and Supports       130,806       119,016         Compression Therapy (Phlebology)       12,359       12,345         Other products       1,363       1,811         263,926       242,709         Specified according to currency:         US Dollar, USD       131,524       119,894         Euro, EUR       86,546       82,502         British Pound, GBP       13,799       14,067         Canadian dollar, CAD       11,943       10,521         Swedish Krona, SEK       9,199       7,544         Norwegian Krona, NOK       5,499       4,278         Australian Dollar, AUD       2,684       1,868         Icelandic Krona, ISK       967       725         Other       1,765       1,310         Other       263,926       242,709		YTD 2010	YTD 2009
Asia         11,962         10,532           263,926         242,709           Specified according to product lines:           Prosthetics           Bracing and Supports         130,806         119,016           Compression Therapy (Phlebology)         12,359         12,345           Other products         1,303         1,811           263,926         242,709           Specified according to currency:         131,524         119,894           Euro, EUR         86,546         82,502           British Pound, GBP         13,799         14,067           Canadian dollar, CAD         11,943         10,521           Swedish Krona, SEK         9,199         7,544           Norwegian Krona, NOK         5,499         4,278           Australian Dollar, AUD         2,684         1,868           Icelandic Krona, ISK         967         725           Other         1,765         1,310	Americas	136,303	118,969
263,926         242,709           Specified according to product lines:           Prosthetics         119,398         109,537           Bracing and Supports         130,806         119,016           Compression Therapy (Phlebology)         12,359         12,345           Other products         1,363         1,811           263,926         242,709           Specified according to currency:         131,524         119,894           Euro, EUR         86,546         82,502           British Pound, GBP         13,799         14,067           Canadian dollar, CAD         11,943         10,521           Swedish Krona, SEK         9,199         7,544           Norwegian Krona, NOK         5,499         4,278           Australian Dollar, AUD         2,684         1,868           Icelandic Krona, ISK         967         725           Other         1,765         1,315	EMEA	115,661	113,209
Specified according to product lines:         Prosthetics	Asia	11,962	10,532
Prosthetics		263,926	242,709
Bracing and Supports.       130,806       119,016         Compression Therapy (Phlebology).       12,359       12,345         Other products.       1,363       1,811         263,926       242,709         Specified according to currency:         US Dollar, USD.       131,524       119,894         Euro, EUR.       86,546       82,502         British Pound, GBP.       13,799       14,067         Canadian dollar, CAD       11,943       10,521         Swedish Krona, SEK.       9,199       7,544         Norwegian Krona, NOK.       5,499       4,278         Australian Dollar, AUD.       2,684       1,868         Icelandic Krona, ISK.       967       725         Other.       1,765       1,310	Specified according to product lines:		
Compression Therapy (Phlebology).       12,359       12,345         Other products.       1,363       1,811         Z63,926       242,709         Specified according to currency:         US Dollar, USD.       131,524       119,894         Euro, EUR.       86,546       82,502         British Pound, GBP.       13,799       14,067         Canadian dollar, CAD.       11,943       10,521         Swedish Krona, SEK.       9,199       7,544         Norwegian Krona, NOK.       5,499       4,278         Australian Dollar, AUD.       2,684       1,868         Icelandic Krona, ISK.       967       725         Other.       1,765       1,310	Prosthetics	119,398	109,537
Other products       1,363       1,811         263,926       242,709         Specified according to currency:         US Dollar, USD       131,524       119,894         Euro, EUR       86,546       82,502         British Pound, GBP       13,799       14,067         Canadian dollar, CAD       11,943       10,521         Swedish Krona, SEK       9,199       7,544         Norwegian Krona, NOK       5,499       4,278         Australian Dollar, AUD       2,684       1,868         Icelandic Krona, ISK       967       725         Other       1,765       1,310	Bracing and Supports	130,806	119,016
Z63,926         242,709           Specified according to currency:           US Dollar, USD.         131,524         119,894           Euro, EUR.         86,546         82,502           British Pound, GBP.         13,799         14,067           Canadian dollar, CAD.         11,943         10,521           Swedish Krona, SEK.         9,199         7,544           Norwegian Krona, NOK.         5,499         4,278           Australian Dollar, AUD.         2,684         1,868           Icelandic Krona, ISK.         967         725           Other.         1,765         1,310	Compression Therapy (Phlebology)	12,359	12,345
Specified according to currency:         US Dollar, USD	Other products	1,363	1,811
US Dollar, USD.       131,524       119,894         Euro, EUR.       86,546       82,502         British Pound, GBP.       13,799       14,067         Canadian dollar, CAD.       11,943       10,521         Swedish Krona, SEK.       9,199       7,544         Norwegian Krona, NOK.       5,499       4,278         Australian Dollar, AUD.       2,684       1,868         Icelandic Krona, ISK.       967       725         Other.       1,765       1,310		263,926	242,709
Euro, EUR	Specified according to currency:		
British Pound, GBP       13,799       14,067         Canadian dollar, CAD       11,943       10,521         Swedish Krona, SEK       9,199       7,544         Norwegian Krona, NOK       5,499       4,278         Australian Dollar, AUD       2,684       1,868         Icelandic Krona, ISK       967       725         Other       1,765       1,310	US Dollar, USD	131,524	119,894
Canadian dollar, CAD.       11,943       10,521         Swedish Krona, SEK.       9,199       7,544         Norwegian Krona, NOK.       5,499       4,278         Australian Dollar, AUD.       2,684       1,868         Icelandic Krona, ISK.       967       725         Other.       1,765       1,310	Euro, EUR	86,546	82,502
Swedish Krona, SEK.       9,199       7,544         Norwegian Krona, NOK.       5,499       4,278         Australian Dollar, AUD.       2,684       1,868         Icelandic Krona, ISK.       967       725         Other.       1,765       1,310	British Pound, GBP	13,799	14,067
Norwegian Krona, NOK       5,499       4,278         Australian Dollar, AUD       2,684       1,868         Icelandic Krona, ISK       967       725         Other       1,765       1,310	Canadian dollar, CAD	11,943	10,521
Australian Dollar, AUD.       2,684       1,868         Icelandic Krona, ISK.       967       725         Other.       1,765       1,310	Swedish Krona, SEK	9,199	7,544
Icelandic Krona, ISK       967       725         Other       1,765       1,310	Norwegian Krona, NOK	5,499	4,278
Other	Australian Dollar, AUD	2,684	1,868
	Icelandic Krona, ISK	967	725
263,926 242,709	Other	1,765	<b>1,3</b> 10
		263,926	242,709

## 5. Geographical segments

The Company uses geographical markets as its primary segments. Segment information is presented below, according to location of customers:

2010	Americas	EMEA	Asia	Eliminations	Consolidated
	YTD 2010	YTD 2010	YTD 2010	YTD 2010	YTD 2010
Revenue					
External sales	136,303	115,661	11,962	0	263,926
Inter-segment sales	19,296	62,040	0	(81,336)	0
Total revenue	155,599	177,701	11,962	(81,336)	263,926
Inter-segment sales are calculated from produ	ction cost.				
Result					
Segment result	27,749	14,263	3,873	0	45,885
Financial income/(expenses)					(9,512)
Profit before tax					36,373
Income tax					(9,072)
Net profit					27,301
Other information					
Capital additions	3,073	2,693	88	0	5,854
Depreciation and amortization	3,711	6,738	148	0	10,597
Balance sheet 30.09.2010					
Assets Segment assets	392,887	854,520	13,376	(655,400)	605,384
Liabilities Segment liabilities	263,707	472,666	13,162	(478,704)	270,830

2009	Americas YTD 2009	EMEA YTD 2009	Asia YTD 2009	Eliminations YTD 2009	Consolidated YTD 2009
Revenue					
External sales	118,969	113,208	10,532	0	242,709
Inter-segment sales	14,335	41,692	0	(56,027)	0
Total revenue	133,304	154,900	10,532	(56,027)	242,709
Result					
Segment result	16,823	13,739	3,956	0	34,518
Financial income/(expenses)					(14,792)
Profit before tax					19,726
Income tax					(5,038)
Net profit					14,688
Other information	Americas	EMEA	Asia	Eliminations	Consolidated
Capital additions	1,316	4,497	134	0	5,947
Depreciation and amortization	8,007	6,509	143	0	14,659
Balance sheet 31.12.2009					
Assets					
Segment assets	429,724	1,034,923	8,378	(844,808)	628,217
Liabilities					
Segment liabilities	308,668	588,956	8,469	(590,099)	315,994

## 6. Other income

8

Included in other income in 2010 is a gain from sale of office facility in Alisio Viejo, California, amounting to 1.2 million.

## 7. Financial income / (expenses)

Financial income and (expenses) are specified as follows:

				YTD 2010	YTD 2009
	Financial income		•		
	Interests on bank deposits			86	138
	Income from other financial assets			3	11
	Share in profit/loss of associated companies			111	0
	Other financial income			80	36
				280	185
	Finance expenses				
	Interest on bank overdrafts and loans			(11,417)	(11,449)
	Other financial expenses			(316)	(65)
	•			(11,733)	(11,514)
	Net exchange rate differences			1,941	(3,463)
	Net financial income / (expenses)		······································	(9,512)	(14,792)
3.	Income tax				
	Income tax is specified as follows:				
				YTD 2010	YTD 2009
	Current tax expenses			(6,575)	(4,758)
	Deferred tax expenses			(2,568)	(280)
	Deferred tax reclassified from equity to income			71	0
			•	(9,072)	(5,038)
		YTD 20	10	YTD	2009
		Amount	%	Amount	%
	Profit before taxes	36,373		19,726	
	Income tax calculated at 18% / 15%	(6,459)	18%	(2,959)	15%
	Effect of different tax rates of other jurisdictions	(3,052)	8%	(1,052)	5%
	Effect of non-deductible expenses	(376)	1%	(370)	2%
	Effect of change in tax rate	(14)	0%	(32)	0%
	Other changes	829	(2%)	(625)	3%

## 9. Additional information regarding cash flow

	YTD 2010	YTD 2009
Net profit	27,301	14,688
Items not affecting cash	8,643	19,520
Working capital provided by operating activities	35,944	34,208
(Increase) / decrease in inventories	(667)	10,439
(Increase) / decrease in receivables	(5,647)	(1,148)
Increase / (decrease) in payables	1,212	2,821
Net cash provided by operating activities	30,842	46,320

## 10. Property, plant and equipment

Operating fixed assets are specified as follows:				
	Buildings	Machinery	Fixtures	
-	& sites	& equipment	& office equip.	Total
Cost				
At 1 January 2010	15,056	40,337	33,667	89,060
Reclassification	0	(347)	(2,429)	(2,776)
Additions	20	2,340	2,896	5,256
Acquired on acquisition of subsidiary	0	0	12	12
Exchange rate differences	(774)	(566)	(278)	(1,618)
Eliminated on disposal	0	(396)	(2,104)	(2,500)
Fully depreciated assets	0	(5,262)	(3,208)	(8,470)
At 30 September 2010	14,302	36,106	28,556	78,964
Accumulated depreciation				
At 1 January 2010	8,244	25,616	22,914	56,774
Reclassification	0	(388)	(1,299)	(1,687)
Charge for the period	283	2,558	2,528	5,369
Exchange rate differences	(415)	(306)	(115)	(836)
Eliminated on disposal	0	(140)	(1,985)	(2,125)
Fully depreciated assets	0	(5,262)	(3,208)	(8,470)
At 30 September 2010	8,112	22,078	18,835	49,025
Carrying Amount:				
At 30 September 2010	6,190	14,028	9,721	29,939
At 31 December 2009	6,812	14,721	10,753	32,286

Depreciation classified by operational category, is shown in the following schedule:

	YTD 2010	YTD 2009
Cost of goods sold	3,002	2,453
Sales and marketing expenses	399	427
Research and development expenses	377	225
General and administrative expenses	1,591	2,719
	5,369	5,824

#### Assets held for sale

At end of 2009 the Company classified its two office facilities in Aliso Viejo, California as held for sale. In March 2010 it sold one of the buildings for 2.4 million with a sale gain of 1.2 million.

## 11. Goodwill

	0.09.2010
Cost	
At 1 January 2009	322,381
Arising on acquisition of subsidiaries	7,083
Exchange rate differences	5,380
At 31 December 2009	334,844
Arising on acquisition of subsidiaries	1,892
Exchange rate differences	(5,242)
At 30 September 2010	331,494
Carrying amount	
At 30 September 2010	331,494
At 31 December 2009	331,494 334,844

The carrying amount of goodwill was allocated to the following cash-generating units:

Americas	205,312
EMEA	126,611
Asia	2,921
331,494	334,844

## 12. Other intangible assets

	Cust./distrib.		Software and		
	relationships	Patents	Trademarks	other	Total
Cost					
At 1 January 2010	29,019	15,675	35,379	15,484	95,557
Reclassification	18,505	0	(16,771)	1,042	2,776
Additions	0	0	0	598	598
Fully depreciated assets	(2,370)	(3,450)	0	(2,014)	(7,834)
Exchange rate differences	(816)	(22)	(714)	(19)	(1,571)
At 30 September 2010	44,338	12,203	17,894	15,091	89,526
Amortization					
At 1 January 2010	28,308	12,246	6,877	12,744	60,175
Reclassification	5,355	0	(4,905)	1,237	1,687
Charge for the period	1,644	1,456	372	1,756	5,228
Fully depreciated assets	(2,370)	(3,450)	0	(2,014)	(7,834)
Exchange rate differences	(186)	(16)	(37)	(15)	(254)
At 30 September 2010	32,751	10,236	2,307	13,708	59,002
Carrying Amount:					
At 30 September 2010	11,587	1,967	15,587	1,383	30,524
At 31 December 2009	711	3,429	28,502	2,740	35,382

Software was previously classified within Property plant and equipment, but has been reclassified to Other intangible assets. A reclassification was also performed within Other intangible assets. This reclassification does not affect amortization percentage nor the lifetime of these assets.

Amortization classified by operational category, is shown in the following schedule:

	YTD 2010	YTD 2009
Cost of goods sold	15	8
Sales and marketing expenses	2,300	5,937
Research and development expenses	2,062	2,586
General and administrative expenses	851	304
	5,228	8,835

#### 13. The Consolidation

During the period, the Company disposed of 1,5% of it's interest in Team Makena, reducing it continuing interest to 61%. The proceeds on disposal were received in cash.

The Company established a new entity in Mexico during the period, Ossur Mexico, S.de R.L. de C.V

At the end of June the Company acquired 100% of Orthopaedic Partner Africa, which is a sales and distribution company in South Africa. The acquisition has an immaterial effect on the overall financial position of Össur.

#### 14. Other financial assets

Financial assets carried at fair value through profit or loss (FVTPL)

	30.09.2010	31.12.2009
Investment in associates	2,195	1,445
Loans and receivables	2,957	2,122
	5,152	3,567

#### 15. Bank balances and cash

	30.09.2010	31.12.2009
Bank accounts	64,249	76,618
Bankers draft received.	1,441	2,818
Cash and other cash equivalents	91	395
	65,781	79,831

#### 16. Inventories

	30.09.2010	31.12.2009
Raw material	12,876	14,397
Work in progress	3,641	3,170
Finished goods	27,668	25,959
	44,185	43,526

In the preparation of the Consolidated Financial Statements, accumulated gains in inventories from intercompany transactions amounting to 7.7 million (2009: 6.7 million) were eliminated. This has an effect on the income tax expense of the consolidated companies, and an adjustment of 1.8 million (2009: 1.8 million) is made in the Consolidated Financial Statements to reduce income tax expense to account for this.

#### 17. Accounts receivables and other assets

	30.09.2010	31.12.2009
Nominal value	54,126	47,940
Allowances for doubtful accounts	(4,090)	(3,521)
Allowances for sales return	(726)	(726)
	49,310	43,693

#### Other assets

	30.09.2010	31.12.2009
VAT refundable	2,520	1,779
Prepaid expenses	4,306	5,174
Other	3,251	3,460
	10,077	10,413

## 18. Issued capital

Common stock is as follows in millions of shares and USD thousands:

Total share capital at period-end 454	5,068

Total shares issued and outstanding at period-end is 453,732,008 (2009: 454 million). The nominal value of each share is one Icelandic krona.

Changes in share capital are as follows:	Share	Share	Issued
<u> </u>	capital	premium	capital
Balance at 1 January 2009	4,821	168,081	172,902
29,500,000 fully paid ordinary shares 3 November 2009	237	27,572	27,809
1,250,000 fully paid ordinary shares 30 November 2009	10	1,276	1,286
Balance at 31 December 2009	5,068	196,929	201,997
Balance at 30 September 2010	5,068	196,929	201,997

## 19. Stock option contracts and obligations to increase share capital

The following option contracts have been issued at period end:

	Number	Grant date	Exercise date	Exercise price DKK	grant date (Date of conversion to DKK)
1.5.5.1 2005				1	
Issued 5 February 2007	1,540,000	5.2.2007	1.12.2011	7.8	5.5
Issued 8 February 2007	1,250,000	5.2.2007	1.12.2011	7.8	5.5
Issued 23 February 2008	1,950,000	23.2.2008	23.2.2012	6.9	5.5
Issued 15 July 2008	500,000	15.7.2008	15.7.2012	5.4	5.5
Issued 2 March 2009	200,000	2.3.2009	1.3.2013	4.4	5.2
Issued 15 December 2009	400,000	15.12.2009	15.12.2013	5.2	5.2
Issued 2 January 2010	200,000	2.1.2010	2.1.2014	5.3	5.8
Issued 26 May 2010	50,000	26.5.2010	26.5.2014	8.5	8.5
Issued 29 July 2010	100,000	29.7.2010	29.7.2014	8.7	8.7
Total issued option contracts	6,190,000				

Fair value at

Estimated remaining cost due to the stock option contracts are 0.8 million which will be expensed over the next four years. An expense of 0.3 million is recognised in the Income Statement for the period.

In 1.10.2015 - 30.9.2016 / 2015.....

## 20. Borrowings

	Curi	rent	Non - o	current
Secured - at amortized cost	30.09.2010	31.12.2009	30.09.2010	31.12.2009
Loans in USD	9,952	13,641	86,315	102,721
Loans in EUR	10,054	13,022	83,583	104,886
Other borrowings	749	496	3,619	2,675
Bank overdrafts	2	23	0	0
	20,757	27,182	173,517	210,282
Aggregated maturities of long-term loans are as follows:				
			30.09.2010	31.12.2009
In 1.10.2010 - 30.9.2011 / 2010			20,756	27,159
In 1.10.2011 - 30.9.2012 / 2011			27,846	104,006
In 1.10.2012 - 30.9.2013 / 2012			28,113	106,167
In 1.10.2013 - 30.9.2014 / 2013			28,339	0
In 1.10.2014 - 30.9.2015 / 2014			7,856	0

The Company's loan facilities include various provisions that limit certain actions by the Company without prior consulting with the lender. In addition, the loan facilities include certain financial covenants. The Company has pledged all material assets, including buildings, machinery, equipment and inventories to secure banking facilities granted.

81,254

194,273

0

#### 21. Other financial liabilities

Outstanding interest rate swap contracts (cash flow hedge) at 30 September 2010 are due over the next three years. The contracts' fair value is negative 7.6 million and principal amount 129 million.

## 22. Deferred tax asset / (liability)

_	30.09.2010	31.12.2009
At beginning of period.	31,343	34,487
Income tax payable for the period	6,575	4,996
Calculated tax for the period	(9,072)	(7,475)
Reclassification to deferred tax asset/ (liability)	0	(700)
Recognised due to acquisition / disposal of subsidiaries	0	(293)
Recognised directly through equity	(806)	313
Exchange rate differences	(660)	15
	27,380	31,343

The following are the major deferred tax liabilities and assets recognised:

	Assets	Liabilities	Net
Goodwill	27,150	(3,757)	23,393
Intangible assets	546	(5,939)	(5,393)
Operating fixed assets	1,034	(61)	973
Tax loss carry forward	2,625	0	2,625
Inventories	2,064	0	2,064
Provisions	1,149	(700)	449
Current liabilities	1,753	(656)	1,097
Other	2,599	(427)	2,172
Total tax assets / (liabilities)	38,920	(11,540)	27,380
Tax asset and liabilities offsetting	(1,188)	1,188	0
	37,732	(10,352)	27,380

## 23. Provisions

	Current		Non-current	
	30.09.2010	31.12.2009	30.09.2010	31.12.2009
Warranty	506	715	5,328	4,271
Other	1,928	1,971	137	1,473
	2,434	2,686	5,465	5,744

_	Warranty provisions	Restructuring provisions	Other provisions	Total
At 1 January 2009	6,539	3,017	1,678	11,234
Additional provision recognised	3,633	0	1,157	<b>4,</b> 790
Utilization of provision	(3,686)	(2,753)	(264)	(6,703)
Exchange differences	0	(264)	0	(264)
Reclassification.	(1,500)	0	873	(627)
At 31 December 2009	4,986	0	3,444	8,430
Additional provision recognised	2,352	0	651	3,003
Utilization of provision	(1,504)	0	(1,874)	(3,378)
Exchange differences	0	0	(156)	(156)
At 30 September 2010	5,834	0	2,065	7,899
Non-current	5,328	0	137	5,465
Current	506	0	1,928	2,434
At 30 September 2010	5,834	0	2,065	7,899

## 24. Related party transactions

The Company had no material transactions with related parties during the period.

## 25. Other liabilities

	30.09.2010	31.12.2009
Accrued expenses	7,976	11,999
Accrued salaries and related expenses	15,867	14,760
Accrued Royalties	1,174	1,185
Sales tax and VAT	225	934
Payable due to previous acquisition	2,324	2,324
Other	3,430	2,075
	30,996	33,276

#### 26. Litigation

On 5 December 2006, Össur hf., parent company of Össur North America Inc. and Royce Medical Inc., Össur America's predecessor companies, disclosed to the Office of Inspector General of the U.S. Department of Defence that Össur North America, Inc. and Royce Medical Company may have made some sales to the government that were not consistent with the requirements of the Buy American Act or Trade Agreements Act. A review was conducted by third party experts of the sales and the circumstances surrounding the sales. The review's conclusions were sent in a report to the Inspector General of the Department of Defence in the last quarter of 2007. The likely outcome of this matter remains uncertain.

#### 27. Approval of the Consolidated Financial Statements

The Condensed Interim Consolidated Financial Statements were approved by the board of directors and authorised for issue on 25 October 2010.